Want to see OM full AI Analyst Report?
OM Stock Chart & Stats
$4.35
-$0.10(-9.09%)
At close: 4:00 PM EST
$4.35
-$0.10(-9.09%)
Day’s Range― - ―
52-Week Range$3.00 - $19.60
Previous CloseN/A
Volume1.92M
Average Volume (3M)277.23K
Market Cap
$84.06M
Enterprise Value$15.46
Total Cash (Recent Filing)$156.71M
Total Debt (Recent Filing)$101.61M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Aug 05, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.16
Shares Outstanding18,537,241
10 Day Avg. Volume185,866
30 Day Avg. Volume277,225
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.47
P/FCF Ratio-1.20
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.67Price Target Upside76.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.89
Revenue Forecast (FY)$126.60M
Bulls Say, Bears Say
Bulls Say
Gross Margin ExpansionSustained gross margin improvement (to ~43.8% non‑GAAP) indicates stronger unit economics and price/cost leverage in Tablo products and consumables. Durable margin expansion improves the path to profitability, funds reinvestment, and reduces dependence on external financing over the next several quarters.
Recurring Revenue MixA high recurring revenue share (~70%) from consumables and services creates predictable demand tied to installed base utilization. This pull‑through model supports steady cash flow per deployed console and offers durable revenue visibility as installations scale across care settings.
Strong Liquidity & Low LeverageA large cash balance combined with minimal debt materially lowers near‑term refinancing risk and gives management runway to execute the next‑gen rollout and commercial plans. Lower burn guidance (<$40M FY) further extends runway and reduces dilution risk over the coming 2–6 months.
Bears Say
Persistent Losses & Negative FCFDespite margin gains, the company remains deeply unprofitable with large negative net margins and consistently negative free cash flow. This structural loss profile keeps funding and dilution risk elevated until operating profits and positive cash generation become sustained and material.
Revenue Lumpiness & Timing RiskHeavy reliance on uneven capital order timing and back‑half loaded growth makes near‑term revenue volatile. This structural lumpiness complicates planning for production, inventory and salesforce deployment and raises execution risk if expected late‑year orders or next‑gen adoption are delayed.
Leadership Transition & Execution RiskDeparture of a senior R&D/ops/service executive during a critical next‑generation product rollout increases execution risk. Combined with dependence on the new Tableau launch for back‑half growth, leadership turnover could slow deployments, product support scale and time‑to‑adoption.
Outset Medical News
OM FAQ
What was Outset Medical, Inc.’s price range in the past 12 months?
Outset Medical, Inc. lowest stock price was $3.00 and its highest was $19.60 in the past 12 months.
What is Outset Medical, Inc.’s market cap?
Outset Medical, Inc.’s market cap is $84.06M.
When is Outset Medical, Inc.’s upcoming earnings report date?
Outset Medical, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 19 days.
How were Outset Medical, Inc.’s earnings last quarter?
Outset Medical, Inc. released its earnings results on May 07, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.79 by -$0.04.
Is Outset Medical, Inc. overvalued?
According to Wall Street analysts Outset Medical, Inc.’s price is currently Undervalued.
Does Outset Medical, Inc. pay dividends?
Outset Medical, Inc. does not currently pay dividends.
What is Outset Medical, Inc.’s EPS estimate?
Outset Medical, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Outset Medical, Inc. have?
Outset Medical, Inc. has 18,537,241 shares outstanding.
What happened to Outset Medical, Inc.’s price movement after its last earnings report?
Outset Medical, Inc. reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.79. Following the earnings report the stock price went down -21.047%.
Which hedge fund is a major shareholder of Outset Medical, Inc.?
Currently, no hedge funds are holding shares in OM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outset Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.67 (76.25% Upside)
$7.67 (76.25% Upside)
Blogger Sentiment
Bullish
OM Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.91%
12-Months-Change
Fundamentals
Return on Equity
-55.88%
Trailing 12-Months
Asset Growth
-17.18%
Trailing 12-Months
Company Description
Outset Medical, Inc.
Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features. Founded in 2003, the company initially operated under the name Home Dialysis Plus, Ltd. before rebranding to Outset Medical, Inc. in January 2015. Its corporate headquarters are located in San Jose, California.
OM Revenue Breakdown
47.04% Consoles
32.37% Consumables
20.59% Service and other revenue
OM Stock 12 Month Forecast
Average Price Target
$7.67
▲(76.25% Upside)
Technical Analysis
Ownership Overview
19.26% Insiders
21.41% Mutual Funds
2.10% Other Institutional Investors
51.58% Public Companies and
Individual Investors